Pūrgo™ Air Purification & Sanitization Devices to Be Installed at HSS in NYC

Pūrgo™: AeroClean Technologies (“AeroClean”) (Nasdaq: AERC) announced Hospital for Special Surgery (“HSS”) in New York will install Pūrgo™ air purification and sanitization devices in their facilities starting in early 2022.

Pūrgo™ utilizes patented, proprietary, UV-C LED technology to significantly reduce or remove harmful pathogens like allergens, mold, bacteria, fungi and viruses, including the surrogate pathogen for COVID-19 – offering continuous air sanitization as an additional important safety measure for patients, staff and visitors.

HSS, the #1 ranked hospital in the US for orthopedics for 12 years, best in the northeast for rheumatology and top-ranked in pediatric orthopedics, will start deployment of the Pūrgo™ units in non-clinical areas with high staff, patient and visitor traffic. Following deployment in non-clinical areas, HSS is evaluating opportunities for a broader deployment of Pūrgo™ devices to other areas, including new surgical locations, outpatient treatment areas, medical office buildings and other spaces where supplemental, localized air sanitization will be needed.

“As the world’s largest academic medical center specialized in musculoskeletal care, we have the responsibility and opportunity to implement the systems that will create the safest possible environment,” said Dr. Bryan Kelly, HSS Surgeon in Chief and Medical Director.

HSS also plans to test and validate AeroClean’s new clean air technology for elevators, Pūrgo™ Lift. These devices will be installed in an HSS public elevator in February 2022 and evaluated for future deployment across HSS facilities.

“Implementing cutting-edge technology is necessary as part of our commitment to providing the best care for our patients, staff and visitors,” said Mark Healey, HSS Assistant Vice President, Facilities and Environmental Services.

Pūrgo will continuously work to purify and eliminate viruses and other pollutants from the air, continuously increasing local air exchange to help prevent the transmission of harmful pathogens indoors.

“We are proud to provide HSS with a real-time solution that can be deployed safely in any of their spaces to purify the air and add a supplemental layer of protection for everyone who enters their facilities,” said Jason DiBona, CEO of AeroClean.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version